Disease · HP_0010783
Erythema
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Erythema. Diseases, record HP_0010783. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0010783
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Erythema
- Open Targets ID
- HP_0010783
- Other names
- Redness of skin or mucous membrane
- Highest stage of its drugs
- Approval, for 4 of its 10 drugs, from DailyMed and TTD
Source Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AZELAIC ACID | CHEMBL1238 | Small molecule | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets |
| BRIMONIDINE TARTRATE | CHEMBL1200389 | Small molecule | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets |
| CHLOROXINE | CHEMBL1200596 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| SELENIUM SULFIDE | CHEMBL1200680 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| ERENUMAB | CHEMBL3833329 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TETRASUL | CHEMBL1365576 | Small molecule | Phase 2 | TTD | 1 | 0 | 0 | Drugs and targets |
| OXYMETAZOLINE HYDROCHLORIDE | CHEMBL1200791 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| STRONTIUM CHLORIDE HEXAHYDRATE | CHEMBL1909080 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALBENDAZOLE | CHEMBL1483 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METRONIDAZOLE | CHEMBL137 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets7
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRA2A | Adrenergic receptor alpha | 2 | Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonist | Approval | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha | 2 | Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonist | Approval | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha | 2 | Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonist | Approval | https://conductscience.org/library/genes/152 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha agonist | Phase 1 | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha agonist | Phase 1 | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha | 1 | Adrenergic receptor alpha agonist | Phase 1 | https://conductscience.org/library/genes/146 | Drugs and targets |
| CALCRL | Calcitonin gene-related peptide type 1 receptor | 1 | Calcitonin gene-related peptide type 1 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/10203 | Drugs and targets |
Trials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01659853 | Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea | Phase 3 | 70 | 2014-07-10 | Erythema, Rosacea | AZELAIC ACID, BRIMONIDINE TARTRATE | Its record names the disease | ClinicalTrials.gov |
| NCT01579084 | Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea | Phase 1 | 64 | 2013-11-15 | Rosacea, Erythema | OXYMETAZOLINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT05208333 | The Effectiveness of Albendazole Treatment Among Infected Toxocara Children | Not applicable | 960 | Toxocara Infection | ALBENDAZOLE | Its record names the disease | ClinicalTrials.gov | |
| NCT01301677 | Ultra Violet B Radiation (UVR) Study of Strontium Chloride Hexahydrate Hydrocortisone | Phase 1 | 47 | Erythema, Pain | STRONTIUM CHLORIDE HEXAHYDRATE | Its record names the disease | ClinicalTrials.gov | |
| NCT00668655 | An Evaluation of the Cosmetic Appearance of Metronidazole Gel (MetroGel®) 1% | 30 | Rosacea | METRONIDAZOLE | Its record names the disease | ClinicalTrials.gov | ||
| NCT04419259 | Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea | Phase 2 | 30 | Rosacea | ERENUMAB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| CD07805/47 Gel 0.5 and Vehicle vs Azelaic Acid 15%: serious adverse events | 0 of 70 | 0 of 68 | 138 | NCT01659853 |
Source Trial comparisons
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0010783
GET https://conductscience.org/api/diseases/v1/HP_0010783/drugs